1. Occurrence and prognostic relevance of CD30 expression in post-transplant lymphoproliferative disorders
- Author
-
Bente Jespersen, Esben Søndergård, Jan Kampmann, Søren Schwartz Sørensen, Eva Futtrup Maksten, Stephen Hamilton-Dutoit, Patricia Switten Nielsen, Maja Ølholm Vase, Michael Boe Møller, Francesco d'Amore, Claus Yding Andersen, and Knud Bendix
- Subjects
Adult ,Male ,Oncology ,Epstein-Barr Virus Infections ,Herpesvirus 4, Human ,Cancer Research ,medicine.medical_specialty ,Adolescent ,CD30 ,medicine.medical_treatment ,Ki-1 Antigen ,Lymphoproliferative disorders ,Biology ,Young Adult ,Postoperative Complications ,immune system diseases ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Child ,Brentuximab vedotin ,Aged ,Chemotherapy ,Tissue microarray ,Organ Transplantation ,Hematology ,Middle Aged ,Prognosis ,medicine.disease ,Lymphoproliferative Disorders ,Lymphoma ,Immunoconjugate ,CD30 PTLD EBV cell-of-origin EPSTEIN-BARR-VIRUS B-CELL LYMPHOMA HODGKINS-LYMPHOMA BRENTUXIMAB VEDOTIN SOLUBLE CD30 INFECTION SURVIVAL MARKER IMPACT TISSUE ,Tissue Array Analysis ,Child, Preschool ,Immunology ,Female ,Rituximab ,medicine.drug - Abstract
Post-transplant lymphoproliferative disorders (PTLDs) are potentially fatal, often Epstein-Barr virus (EBV)-driven neoplasias developing in immunocompromised hosts. Initial treatment usually consists of a reduction in immunosuppressive therapy and/or rituximab with or without chemotherapy. However, patients who relapse do poorly, and new treatment options are warranted. With the introduction of the immunoconjugate brentuximab vedotin, the CD30 antigen has become an effectively targetable molecule. Therefore, we investigated the frequency and level of CD30 expression in PTLDs. We identified 108 patients with PTLDs diagnosed during 1994-2011, of whom 62 had adequate paraffin-embedded tissue for tissue microarray construction. Immunohistochemical expression of CD30 was consistently detected in all types of PTLD (overall 85.25%), including the monomorphic subtypes, and was correlated with a more favorable outcome. For diffuse large B-cell lymphoma (DLBCL)-type PTLD this was regardless of EBV status, and remained significant in multivariate analysis. Cell-of-origin had no independent prognostic value in our series of DLBCL PTLD.
- Published
- 2015
- Full Text
- View/download PDF